ABT-199 (Venectoclax)
-- C-1008
- Targets: BCL-2
- Synonym: ABT199; ABT-199; ABT 199; GDC0199; GDC0199; GDC 0199; RG7601; RG7601; RG 7601; Venetoclax
- Chemical Name/IUPAC:4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
-
Technical Data
- Product Name: ABT-199 (Venectoclax)
- Chemical Formula: C45H50ClN7O7S
- Molecular Weight: 868.44
- CAS#: 1257044-40-8
- Appearance: Solid powder
- Purity: > 99% by HPLCLaboratory Supplies
- Solubility: Soluble in DMSO
- Storage: Room temperature for months, or -20ºC for Three years
-
Description
ABT-199 (venetoclax) is an orally bioavailable and selective small-molecule inhibitor of the anti-apoptotic protein BCL-2 with potential antineoplastic activity. ABT-199 mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of BCL-2 proteins, thereby repressing BCL-2 activity and restoring apoptotic processes in tumor cells.